Update for rapid antigen tests for the direct detection of SARS-CoV-2 coronavirus, which are the subject of the claim under Section 1(1) of the Coronavirus Test Regulation (TestV).
With the amendment of the Coronavirus Test Regulation (TestV) effective June 29, 2022, there are new regulations for the reimbursement of rapid antigen tests. The entitlement under the first sentence of Section 1(1) to the use of point-of-care (PoC) antigen tests for diagnostic purposes is limited to antigen tests that are already included in the combined list of corona antigen rapid tests (Common RAT List) of the HSC (Health Security Committee of the European Union).
The list also contains information on the criteria included in this list and is now available on the EU website:
The market overview in the BfArM list according to § 1 paragraph 1 sentence 6 TestV (old) as well as the list with the Comparative Evaluation of the Sensitivity of SARS-CoV-2 Antigen Rapid Tests were thus discontinued.
All tests that we have in our range meet these criteria and are therefore also reimbursable under the new regulation.